GlobeNewsWire
12 Jun 2026, 13:44 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Erasca reported a patient death linked to a Grade 5 pneumonitis event during Phase 1 clinical trials of ERAS-0015. — Patient fatalities in early-stage clinical trials are severe safety signals that can lead to trial halts or drug failure.
-0.90Revolution Medicines (RevMed) has alleged that Erasca's ERAS-0015 infringes on its patents and involves trade secret misappropriation. — Intellectual property disputes and misappropriation claims threaten the commercial viability and legal right to sell a lead drug candidate.
-0.70Erasca is facing a federal securities class action lawsuit alleging it made misleading statements regarding ERAS-0015's preclinical data. — Class action lawsuits create legal liabilities and signal systemic governance or transparency issues to investors.
-0.40Continue reading
6 related stories
Top 2 movers · tap to explore
Erasca admitted that preclinical comparisons between ERAS-0015 and RMC-6236 were not based on head-to-head trials and are inherently limited. — This admission undermines the perceived competitive advantage of the drug candidate over its rival.
-0.30Which stocks this story touches
The company is facing a securities class action lawsuit, allegations of patent infringement and trade secret misappropriation, and reports of a patient death in a clinical trial.
The company is the party alleging patent infringement and trade secret misappropriation against a competitor.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
48m ago
